Skip to content

Author

Ayşe Nuransoy Cengiz

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center

Aims: Fifty percent of patients with metastatic renal cell carcinoma (RCC) die within the first year. Therefore, survival in the first-line setting is of paramount importance. Cabozantinib has been introduced for use in the first-line setting. We plan to conduct a study on its contribution to survival in Turkiye's popu...

Muhammet Cengiz, Ayşe Nuransoy Cengiz, O. Bozkurt et al. · 0 citations
Open access Oct 2026

Receptor Status Changes, HER2-Low Discordance, and TNBC Transformation in Metastatic Breast Cancer: Prognostic Significance and Impact on Survival Outcomes

Background/Objectives: Therapeutic options for metastatic breast cancer vary according to hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, and, importantly, the newly recognized HER2-low status. In triple-negative breast cancer (TNBC), characterized by the absence of HR and HER2 rec...

Ayşe Nuransoy Cengiz, Muhammet Cengiz, O. Bozkurt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.